Last reviewed · How we verify
AN2690, 5%
At a glance
| Generic name | AN2690, 5% |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail (PHASE3)
- Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail (PHASE3)
- Study of Different Doses of a Novel Treatment for Onychomycosis (PHASE2)
- An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents (PHASE4)
- Study of Different Doses of a Novel Treatment for Onychomycosis (PHASE2)
- Safety and Efficacy Evaluation of Topically Applied AN2690 Solutions for Subjects With Onychomycosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |